Sponsored

Radiopharm (ASX:RAD) reports encouraging additional data from brain metastases imaging trial

November 23, 2022 01:09 AM GMT | By Aditi Sarkar
 Radiopharm (ASX:RAD) reports encouraging additional data from brain metastases imaging trial
Image source: company update

Highlights

  • Radiopharm’s shares gained more than 4% in the early hours of 23 November post a new update on Phase II imaging trial in brain metastases.
  • Additional data related to F-18 Pivalate in Phase II imaging trial on brain metastases showed maximum standardised uptake within lesions.
  • Radiopharm’s CEO stated that obtaining a quality image implies another positive step for the potential of the Pivalate technology for the company.

Radiopharm Theranostics (ASX:RAD) has provided an upbeat update concerning F-18 Pivalate (RAD 101), its lead product candidate for brain metastases.

The company stated that Imperial College London has provided further data related to the Phase 2a imaging trial of the compound in patients with brain metastases.

High contrast images seen at 60 minutes after the injection of Pivalate showed the maximum standardised uptake within lesions. The results were significantly different compared to the mean.

Image source: Company update

Image description: High contrast images seen after Pivalate injection

As per the company’s CEO Riccardo Canevari, this is a promising indication and yet another positive step for the potential of the Pivalate technology for Radiopharm.

More to come…

Shares of Radiopharm were trading at AU$0.120 with an uptick of around 4.347% in the early hours of 23 November 2022.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


AI on the Rise: A Look at Top AI Companies and Their Stocks

Send OTP Resend OTP in 30s

Sponsored Articles


Investing Ideas

Previous Next